TY - JOUR
T1 - Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy
AU - Kok, Dieuwertje E.
AU - van den Berg, Maaike M.G.A.
AU - Posthuma, Liesbeth
AU - van ’t Erve, Iris
AU - van Duijnhoven, Fränzel J.B.
AU - de Roos, Wilfred K.
AU - Grosfeld, Sissi
AU - Los, Maartje
AU - Sommeijer, Dirkje W.
AU - van Laarhoven, Hanneke W.M.
AU - Winkels, Renate M.
AU - Kampman, Ellen
N1 - Funding Information:
This work was supported by the Dutch Cancer Society [grant number UW2011-4987], [grant number UW2011-5268]. We gratefully acknowledge all COBRA participants. We would like to thank staff of the following hospitals: Ziekenhuis Gelderse Vallei, Maxima Medisch Centrum, Reinier de Graaf Ziekenhuis, Onze Lieve Vrouwen Gasthuis, Amphia Ziekenhuis, Canisius Wilhelmina Ziekenhuis, Radboud Universitair Medisch Centrum, Alexander Monro Ziekenhuis, St. Antonius Ziekenhuis, St. Anna Ziekenhuis and Flevoziekenhuis. We thank Hendriek Boshuizen for her statistical advice and Yfke de Vries, Anja de Kruijf, Celine Kelfkens, Lisette Kamps, and Monique Derks for their assistance during recruitment of the participants and collection of data.
Funding Information:
This work was supported by the Dutch Cancer Society [grant number UW2011-4987], [grant number UW2011-5268].
Publisher Copyright:
© 2019, © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2019/7/4
Y1 - 2019/7/4
N2 - Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D 3 ) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D 3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D 3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D 3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D 3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D 3 levels after chemotherapy. We reported lower 25(OH)D 3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D 3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.
AB - Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D 3 ) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D 3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D 3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D 3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D 3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D 3 levels after chemotherapy. We reported lower 25(OH)D 3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D 3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.
UR - http://www.scopus.com/inward/record.url?scp=85060334832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060334832&partnerID=8YFLogxK
U2 - 10.1080/01635581.2018.1559938
DO - 10.1080/01635581.2018.1559938
M3 - Article
C2 - 30661404
AN - SCOPUS:85060334832
VL - 71
SP - 756
EP - 766
JO - Nutrition and Cancer
JF - Nutrition and Cancer
SN - 0163-5581
IS - 5
ER -